Leukemia - Table of Contents alert Volume 31 Issue 12

If you are unable to see the message below, click here to view.

Advertisement Come and visit us at the ASH meeting in Atlanta, Dec 9 - 11th, booth #48 Springer Nature will be at the American Society for Hematology annual meeting in Atlanta. Pick up your complimentary copy of Leukemia, Bone Marrow Transplantation, Oncogene, Nature or Nature Reviews Clinical Oncology. We look forward to welcoming you!   TABLE OF CONTENTS Volume 31, Issue 12 (December 2017) In this issue Original Articles Letters to the Editor Corrigenda Also new AOP   Sign up for e-alerts Recommend to your library Web feed Follow on Twitter Subscribe Advertisement Celebrating 30 years of Leukemia — 1987 to 2017 Thank you to the editors, board members, contributors, reviewers and readers, past and present for their invaluable contributions, and for bringing the journal to this milestone. Watch our anniversary video showing a brief impact overview >>>   Original Articles Top ACUTE MYELOID LEUKEMIA Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways OPEN Y Lyu, J Lou, Y Yang, J Feng, Y Hao, S Huang, L Yin, J Xu, D Huang, B Ma, D Zou, Y Wang, Y Zhang, B Zhang, P Chen, K Yu, E W-F Lam, X Wang, Q Liu, J Yan and B Jin Leukemia 2017 31: 2543-2551; advance online publication, April 12, 2017; 10.1038/leu.2017.116 Abstract | Full Text Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia OPEN E Bernson, A Hallner, F E Sander, O Wilsson, O Werlenius, A Rydström, R Kiffin, M Brune, R Foà, J Aurelius, A Martner, K Hellstrand and F B Thorén Leukemia 2017 31: 2552-2559; advance online publication, May 22, 2017; 10.1038/leu.2017.151 Abstract | Full Text Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study A B Halpern, M Othus, E M Huebner, S A Buckley, E L Pogosova-Agadjanyan, K F Orlowski, B L Scott, P S Becker, P C Hendrie, T L Chen, M-E M Percival, E H Estey, D L Stirewalt and R B Walter Leukemia 2017 31: 2560-2567; advance online publication, May 30, 2017; 10.1038/leu.2017.165 Abstract | Full Text ACUTE LYMPHOBLASTIC LEUKEMIA JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias OPEN C Delgado-Martin, L K Meyer, B J Huang, K A Shimano, M S Zinter, J V Nguyen, G A Smith, J Taunton, S S Winter, J R Roderick, M A Kelliher, T M Horton, B L Wood, D T Teachey and M L Hermiston Leukemia 2017 31: 2568-2576; advance online publication, May 9, 2017; 10.1038/leu.2017.136 Abstract | Full Text Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia OPEN A Elder, S Bomken, I Wilson, H J Blair, S Cockell, F Ponthan, K Dormon, D Pal, O Heidenreich and J Vormoor Leukemia 2017 31: 2577-2586; advance online publication, May 10, 2017; 10.1038/leu.2017.140 Abstract | Full Text High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients J Pan, J F Yang, B P Deng, X J Zhao, X Zhang, Y H Lin, Y N Wu, Z L Deng, Y L Zhang, S H Liu, T Wu, P H Lu, D P Lu, A H Chang and C R Tong Leukemia 2017 31: 2587-2593; advance online publication, May 15, 2017; 10.1038/leu.2017.145 Abstract | Full Text Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia M Tesio, A Trinquand, P Ballerini, G Hypolite, L Lhermitte, A Petit, N Ifrah, A Baruchel, H Dombret, E Macintyre and V Asnafi Leukemia 2017 31: 2594-2600; advance online publication, May 25, 2017; 10.1038/leu.2017.157 Abstract | Full Text CHRONIC LYMPHOCYTIC LEUKEMIA Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition E Slinger, R Thijssen, A P Kater and E Eldering Leukemia 2017 31: 2601-2607; advance online publication, May 2, 2017; 10.1038/leu.2017.129 Abstract | Full Text Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells OPEN J Yu, L Chen, Y Chen, M K Hasan, E M Ghia, L Zhang, R Wu, L Z Rassenti, G F Widhopf, Z Shen, S P Briggs and T J Kipps Leukemia 2017 31: 2608-2614; advance online publication, May 3, 2017; 10.1038/leu.2017.132 Abstract | Full Text Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells OPEN M K Hasan, J Yu, L Chen, Bing Cui, G F Widhopf II, L Rassenti, Z Shen, S P Briggs and T J Kipps Leukemia 2017 31: 2615-2622; advance online publication, May 3, 2017; 10.1038/leu.2017.133 Abstract | Full Text LYMPHOMA High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group B Kasenda, G Ihorst, R Schroers, A Korfel, I Schmidt-Wolf, G Egerer, L von Baumgarten, A Röth, J Bloehdorn, R Möhle, M Binder, U Keller, M Lamprecht, M Pfreundschuh, E Valk, H Fricker, E Schorb, K Fritsch, J Finke and G Illerhaus Leukemia 2017 31: 2623-2629; advance online publication, May 31, 2017; 10.1038/leu.2017.170 Abstract | Full Text MULTIPLE MYELOMA, GAMMOPATHIES Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes OPEN P Hari, M-V Mateos, R Abonour, S Knop, W Bensinger, H Ludwig, K Song, R Hajek, P Moreau, D S Siegel, S Feng, M Obreja, S K Aggarwal, K Iskander and H Goldschmidt Leukemia 2017 31: 2630-2641; advance online publication, April 25, 2017; 10.1038/leu.2017.122 Abstract | Full Text E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271 OPEN A Natoni, T A G Smith, N Keane, C McEllistrim, C Connolly, A Jha, M Andrulis, E Ellert, M S Raab, S V Glavey, L Kirkham-McCarthy, S K Kumar, S C Locatelli-Hoops, I Oliva, W E Fogler, J L Magnani and M E O'Dwyer Leukemia 2017 31: 2642-2651; advance online publication, April 25, 2017; 10.1038/leu.2017.123 Abstract | Full Text A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells A Ray, D S Das, Y Song, V Macri, P Richardson, C L Brooks, D Chauhan and K C Anderson Leukemia 2017 31: 2652-2660; advance online publication, May 8, 2017; 10.1038/leu.2017.135 Abstract | Full Text KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival H Ohguchi, T Harada, M Sagawa, S Kikuchi, Y-T Tai, P G Richardson, T Hideshima and K C Anderson Leukemia 2017 31: 2661-2669; advance online publication, May 10, 2017; 10.1038/leu.2017.141 Abstract | Full Text HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications T Harada, H Ohguchi, Y Grondin, S Kikuchi, M Sagawa, Y-T Tai, R Mazitschek, T Hideshima and K C Anderson Leukemia 2017 31: 2670-2677; advance online publication, May 11, 2017; 10.1038/leu.2017.144 Abstract | Full Text Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma M Favreau, E Menu, D Gaublomme, K Vanderkerken, S Faict, K Maes, E De Bruyne, S Govindarajan, M Drennan, S Van Calenbergh, X Leleu, L Zabeau, J Tavernier, K Venken and D Elewaut Leukemia 2017 31: 2678-2685; advance online publication, May 11, 2017; 10.1038/leu.2017.146 Abstract | Full Text Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth J Delgado-Calle, J Anderson, M D Cregor, K W Condon, S A Kuhstoss, L I Plotkin, T Bellido and G D Roodman Leukemia 2017 31: 2686-2694; advance online publication, May 22, 2017; 10.1038/leu.2017.152 Abstract | Full Text Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma OPEN P G Richardson, C C Hofmeister, N S Raje, D S Siegel, S Lonial, J Laubach, Y A Efebera, D H Vesole, A K Nooka, J Rosenblatt, D Doss, M H Zaki, A Bensmaine, J Herring, Y Li, L Watkins, M S Chen and K C Anderson Leukemia 2017 31: 2695-2701; advance online publication, June 2, 2017; 10.1038/leu.2017.173 Abstract | Full Text MYELODYSPLASTIC SYNDROME Preclinical modeling of myelodysplastic syndromes OPEN K Rouault-Pierre, S A Mian, M Goulard, A Abarrategi, A Di Tulio, A E Smith, A Mohamedali, S Best, A-M Nloga, A G Kulasekararaj, L Ades, C Chomienne, P Fenaux, C Dosquet, G J Mufti and D Bonnet Leukemia 2017 31: 2702-2708; advance online publication, June 2, 2017; 10.1038/leu.2017.172 Abstract | Full Text CHRONIC MYELOPROLIFERATIVE NEOPLASMS Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis T Maekawa, Y Osawa, T Izumi, S Nagao, K Takano, Y Okada, N Tachi, M Teramoto, T Kawamura, T Horiuchi, R Saga, S Kato, T Yamamura, J Watanabe, A Kobayashi, S Kobayashi, K Sato, M Hashimoto, S Suzu and F Kimura Leukemia 2017 31: 2709-2716; advance online publication, April 3, 2017; 10.1038/leu.2017.112 Abstract | Full Text Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches OPEN S Pearson, A J K Williamson, R Blance, T C P Somervaille, S Taylor, N Azadbakht, A D Whetton and A Pierce Leukemia 2017 31: 2717-2725; advance online publication, May 23, 2017; 10.1038/leu.2017.143 Abstract | Full Text A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis F Passamonti, T Giorgino, B Mora, P Guglielmelli, E Rumi, M Maffioli, A Rambaldi, M Caramella, R Komrokji, J Gotlib, J J Kiladjian, F Cervantes, T Devos, F Palandri, V De Stefano, M Ruggeri, R T Silver, G Benevolo, F Albano, D Caramazza, M Merli, D Pietra, R Casalone, G Rotunno, T Barbui, M Cazzola and A M Vannucchi Leukemia 2017 31: 2726-2731; advance online publication, May 31, 2017; 10.1038/leu.2017.169 Abstract | Full Text STEM CELL TRANSPLANTATION MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation N Stickel, K Hanke, D Marschner, G Prinz, M Köhler, W Melchinger, D Pfeifer, A Schmitt-Graeff, T Brummer, A Heine, P Brossart, D Wolf, N von Bubnoff, J Finke, J Duyster, J Ferrara, U Salzer and R Zeiser Leukemia 2017 31: 2732-2741; advance online publication, May 9, 2017; 10.1038/leu.2017.137 Abstract | Full Text MOLECULAR TARGETS FOR THERAPY Constitutively active ABL family kinases, TEL/ABL and TEL/ARG, harbor distinct leukemogenic activities in vivo A Yokota, H Hirai, T Shoji, T Maekawa and K Okuda Leukemia 2017 31: 2742-2751; advance online publication, April 7, 2017; 10.1038/leu.2017.114 Abstract | Full Text Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations H Zhang, A Reister Schultz, S Luty, A Rofelty, Y Su, S Means, D Bottomly, B Wilmot, S K McWeeney and J W Tyner Leukemia 2017 31: 2752-2760; advance online publication, April 25, 2017; 10.1038/leu.2017.126 Abstract | Full Text Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response J Long, W Y Fang, L Chang, W H Gao, Y Shen, M Y Jia, Y X Zhang, Y Wang, H B Dou, W J Zhang, J Zhu, A B Liang, J M Li and Jiong Hu Leukemia 2017 31: 2761-2770; advance online publication, May 2, 2017; 10.1038/leu.2017.130 Abstract | Full Text Control of amino acid transport coordinates metabolic reprogramming in T-cell malignancy OPEN K M Grzes, M Swamy, J L Hukelmann, E Emslie, L V Sinclair and D A Cantrell Leukemia 2017 31: 2771-2779; advance online publication, May 26, 2017; 10.1038/leu.2017.160 Abstract | Full Text MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs A R Pyzer, D Stroopinsky, J Rosenblatt, E Anastasiadou, H Rajabi, A Washington, A Tagde, J-H Chu, M Coll, A L Jiao, L T Tsai, D E Tenen, L Cole, K Palmer, A Ephraim, R K Leaf, M Nahas, A Apel, M Bar-Natan, S Jain, M McMasters, L Mendez, J Arnason, B A Raby, F Slack, D Kufe and D Avigan Leukemia 2017 31: 2780-2790; advance online publication, May 30, 2017; 10.1038/leu.2017.163 Abstract | Full Text EARLY PHASE STUDIES Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma A Dispenzieri, C Tong, B LaPlant, M Q Lacy, K Laumann, D Dingli, Y Zhou, M J Federspiel, M A Gertz, S Hayman, F Buadi, M O'Connor, V J Lowe, K-W Peng and S J Russell Leukemia 2017 31: 2791-2798; advance online publication, April 25, 2017; 10.1038/leu.2017.120 Abstract | Full Text A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with 30% blasts OPEN G Garcia-Manero, M A Sekeres, M Egyed, M Breccia, C Graux, J D Cavenagh, H Salman, A Illes, P Fenaux, D J DeAngelo, R Stauder, K Yee, N Zhu, J-H Lee, D Valcarcel, A MacWhannell, Z Borbenyi, L Gazi, S Acharyya, S Ide, M Marker and O G Ottmann Leukemia 2017 31: 2799-2806; advance online publication, May 26, 2017; 10.1038/leu.2017.159 Abstract | Full Text CYTOGENETICS AND MOLECULAR GENETICS Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004 OPEN M Rasche, C von Neuhoff, M Dworzak, J-P Bourquin, J Bradtke, G Göhring, G Escherich, G Fleischhack, N Graf, B Gruhn, O A Haas, T Klingebiel, B Kremens, T Lehrnbecher, A von Stackelberg, J Tchinda, Z Zemanova, C Thiede, N von Neuhoff, M Zimmermann, U Creutzig and D Reinhardt Leukemia 2017 31: 2807-2814; advance online publication, April 25, 2017; 10.1038/leu.2017.121 Abstract | Full Text Genomic determinants of chronic myelomonocytic leukemia B J Patel, B Przychodzen, S Thota, T Radivoyevitch, V Visconte, T Kuzmanovic, M Clemente, C Hirsch, A Morawski, R Souaid, C Saygin, A Nazha, B Demarest, T LaFramboise, H Sakaguchi, S Kojima, H E Carraway, S Ogawa, H Makishima, M A Sekeres and J P Maciejewski Leukemia 2017 31: 2815-2823; advance online publication, May 30, 2017; 10.1038/leu.2017.164 Abstract | Full Text TRANSCRIPTIONAL CONTROL AND SIGNAL TRANSDUCTION, CELL CYCLE RNA editing signature during myeloid leukemia cell differentiation OPEN C Rossetti, E Picardi, M Ye, G Camilli, A M D'Erchia, L Cucina, F Locatelli, L Fianchi, L Teofili, G Pesole, A Gallo and R Sorrentino Leukemia 2017 31: 2824-2832; advance online publication, May 9, 2017; 10.1038/leu.2017.134 Abstract | Full Text Letters to the Editor Top Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group M A Hoechstetter, R Busch, B Eichhorst, A Bühler, D Winkler, M J Eckart, U Vehling-Kaiser, H Schimke, U Jäger, H J Hurtz, G Hopfinger, F Hartmann, H Fuss, W Abenhardt, I Blau, W Freier, L Müller, M Goebeler, C M Wendtner, J Bahlo, K Fischer, M Bentz, B Emmerich, H Döhner, M Hallek and S Stilgenbauer Leukemia 2017 31: 2833-2837; advance online publication, August 14, 2017; 10.1038/leu.2017.246 Full Text The expression of P2Y14, a purinergic G-protein coupled receptor, defines functionally distinct subpopulations in placenta-derived hematopoietic stem progenitor cells S-H Kook, H-J Sim, J-C Lee and B-C Lee Leukemia 2017 31: 2837-2841; advance online publication, August 14, 2017; 10.1038/leu.2017.254 Full Text The C-terminal multimerization domain is essential for leukemia development by CBFβ-SMMHC in a mouse knockin model L Zhao, H Alkadi, E M Kwon, T Zhen, J Lichtenberg, L Alemu, J Cheng, A D Friedman and P P Liu Leukemia 2017 31: 2841-2844; advance online publication, August 18, 2017; 10.1038/leu.2017.262 Full Text Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib W Qiang, O Antelope, M S Zabriskie, A D Pomicter, N A Vellore, P Szankasi, D Rea, J M Cayuela, T W Kelley, M W Deininger and T O’Hare Leukemia 2017 31: 2844-2847; advance online publication, August 18, 2017; 10.1038/leu.2017.264 Full Text Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes A Nazha, K Al-Issa, B K Hamilton, T Radivoyevitch, A T Gerds, S Mukherjee, V Adema, A Zarzour, N Abuhadra, B J Patel, C M Hirsch, A Advani, B Przychodzen, H E Carraway, J P Maciejewski and M A Sekeres Leukemia 2017 31: 2848-2850; advance online publication, August 18, 2017; 10.1038/leu.2017.266 Full Text Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis OPEN A Tefferi, L Saeed, C A Hanson, R P Ketterling, A Pardanani and N Gangat Leukemia 2017 31: 2851-2852; advance online publication, August 18, 2017; 10.1038/leu.2017.268 Full Text Corrigenda Top Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition E Leroy and S N Constantinescu Leukemia 2017 31: 2853; 10.1038/leu.2017.158 Full Text Gene dosage reductions of Trf1 and/or Tin2 induce telomere DNA damage and lymphoma formation in aging mice OPEN K Hartmann, A Illing, F Leithäuser, A Baisantry, L Quintanilla-Martinez and K L Rudolph Leukemia 2017 31: 2853; advance online publication, November 10, 2017; 10.1038/leu.2017.224 Full Text Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol E M C Driessen, P de Lorenzo, M Campbell, M Felice, A Ferster, I Hann, A Vora, L Hovi, G Escherich, C K Li, G Mann, T Leblanc, F Locatelli, A Biondi, J Rubnitz, M Schrappe, L Silverman, J Stary, R Suppiah, T Szczepanski, M Valsecchi and R Pieters Leukemia 2017 31: 2854; 10.1038/leu.2017.279 Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.